Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

McGill University

$105,000.00

Immunotherapy against neuroserpin to correct Nerve Growth Factor metabolic dysfunction and consequent cholinergic and cognitive deficits in a transgenic rat model of Alzheimer's disease.

EF 2016-17

Résumé
Alzheimer's disease (AD) is an increasing problem in our aging population. Unless new disease-modifying treatments are discovered, the problem may become unmanageable. In AD, cholinergic neurons of the basal forebrain become atrophic or die, and most brain cholinergic synapses are lost. Since cholinergic input from these neurons is critical for cognition, these changes are believed to contribute to cognitive decline in AD. Cholinergic neurons depend on a supply of NGF for their survival. We discovered a metabolic pathway that controls the maturation and degradation of NGF in the brain and we documented its deregulation in AD and Mild Cognitive Impairment (a precursor state to AD). Since these disruptions lead to less support of cholinergic neurons by NGF, they could explain cognitive and cholinergic deficits in AD. The McGill-R-Thy1-APP rat model of Alzheimer's disease closely mimics the early human disease condition and provides a good platform for testing therapeutics for Alzheimer's disease. We have identified a key molecule contributing to the disruption of the NGF metabolic pathway: neuroserpin. We propose to infuse an antibody against neuroserpin into the brains of McGill rats; this will lead to more NGF, more support of cholinergic neurons, and may therefore prevent the cognitive problems associated with cholinergic disruption. We will test the animals' cognitive abilities using behavioural tasks, their cholinergic neurons using microscopy, and their NGF processing by measuring protein and mRNA levels. We hypothesize that our antibody will correct deficits in these domains. This approach may provide a better way to save cognitive function in AD than currently exists; current drugs potentiate remaining cholinergic input but do not prevent the atrophy of cholinergic cells. Ideally, this treatment could offer a five-year reprieve from cognitive decline which would have huge benefit for the Canadian economy and healthcare system, as well as AD patients.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
365444
Name
Pentz Rowan D
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Immunotherapy against neuroserpin to correct Nerve Growth Factor metabolic dysfunction and consequent cholinergic and cognitive deficits in a transgenic rat model of Alzheimer's disease.
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Alzhiemer'S Disease; Basal Forebrain; Behavioural Testing; Cholinergic System; Immunotherapy; Inflammation; Nerve Growth Factor; Neurodegeneration; Ngf Metabolic Pathway; Transgenic Models
Abstract
Alzheimer's disease (AD) is an increasing problem in our aging population. Unless new disease-modifying treatments are discovered, the problem may become unmanageable. In AD, cholinergic neurons of the basal forebrain become atrophic or die, and most brain cholinergic synapses are lost. Since cholinergic input from these neurons is critical for cognition, these changes are believed to contribute to cognitive decline in AD. Cholinergic neurons depend on a supply of NGF for their survival. We discovered a metabolic pathway that controls the maturation and degradation of NGF in the brain and we documented its deregulation in AD and Mild Cognitive Impairment (a precursor state to AD). Since these disruptions lead to less support of cholinergic neurons by NGF, they could explain cognitive and cholinergic deficits in AD. The McGill-R-Thy1-APP rat model of Alzheimer's disease closely mimics the early human disease condition and provides a good platform for testing therapeutics for Alzheimer's disease. We have identified a key molecule contributing to the disruption of the NGF metabolic pathway: neuroserpin. We propose to infuse an antibody against neuroserpin into the brains of McGill rats; this will lead to more NGF, more support of cholinergic neurons, and may therefore prevent the cognitive problems associated with cholinergic disruption. We will test the animals' cognitive abilities using behavioural tasks, their cholinergic neurons using microscopy, and their NGF processing by measuring protein and mRNA levels. We hypothesize that our antibody will correct deficits in these domains. This approach may provide a better way to save cognitive function in AD than currently exists; current drugs potentiate remaining cholinergic input but do not prevent the atrophy of cholinergic cells. Ideally, this treatment could offer a five-year reprieve from cognitive decline which would have huge benefit for the Canadian economy and healthcare system, as well as AD patients.
Competitiondate
201610
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Pentz, Rowan D
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~